A research team at the University of Basel has discovered immune cells resident in the lungs that persist long after a bout of flu. Experiments with mice have shown that these helper cells improve the immune response to reinfection by a different strain of the flu virus. The discovery could yield approaches to developing longer-lasting vaccinations against quickly-mutating viruses.
At the start of the coronavirus pandemic, some already began to raise the question of how long immunity lasts after weathering SARS-CoV-2. The same question has now arisen regarding the COVID-19 vaccination. A key role is played by immunological memory—a complex interplay of immune cells, antibodies and signaling substances that allows the body to fight off known pathogens very efficiently.
Researchers led by Professor Carolyn King from the University of Basel’s Department of Biomedicine have now identified a diverse group of immune cells in the lungs that are key to the defense against reinfection by flu viruses. The same could be true of reinfection by other pathogens that cause respiratory diseases.
In experiments with mice, the researchers characterized a group of memory T cells in lung tissue that remain for a long time after a bout of flu. The team reports on these “T resident helper cells” in the peer-reviewed journal Science Immunology.
Reservoir inside tissue
“Relatively little is known about memory T cells that remain in tissue,” explained Nivedya Swarnalekha, co-first author of the study. Previous studies have focused on memory cells in blood and lymphatic tissue. “But it makes sense that the body keeps a reservoir of these cells in the tissues affected by the infection, where the same or similar pathogens could invade again.”
In their study, the researchers describe two types of T helper cells in the lungs. One type releases signaling substances in case of reinfection to equip other immune cells with deadlier “weapons” in the fight against the pathogen. The other type, previously characterized primarily in lymphatic tissue and thought to be absent in lung tissue, assists antibody-producing immune cells (B cells) and localizes closely with them in the lung.
The researchers were able to show that the presence of these cells in the direct proximity of the antibody-producing B cells led to a more efficient immune response against a different flu virus.
Starting point for long-term vaccine protection
Source: Read Full Article